NASDAQ:BPTS - Nasdaq - US09076G2030 - ADR - Currency: USD
8.22
-1.48 (-15.28%)
The current stock price of BPTS is 8.22 USD. In the past month the price decreased by -41.29%. In the past year, price decreased by -94.66%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Biophytis SA operates as a clinical-stage biotechnology company. The company is headquartered in Paris, Ile-De-France and currently employs 26 full-time employees. The company went IPO on 2015-07-13. The firm is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.
BIOPHYTIS SA-ADR
14 avenue de l'Opera
Paris ILE-DE-FRANCE 75252 FR
CEO: Stanislas Veillet
Employees: 26
Company Website: https://www.biophytis.com/
Phone: 33141836600
The current stock price of BPTS is 8.22 USD. The price decreased by -15.28% in the last trading session.
The exchange symbol of BIOPHYTIS SA-ADR is BPTS and it is listed on the Nasdaq exchange.
BPTS stock is listed on the Nasdaq exchange.
8 analysts have analysed BPTS and the average price target is 0.38 USD. This implies a price decrease of -95.36% is expected in the next year compared to the current price of 8.22. Check the BIOPHYTIS SA-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BIOPHYTIS SA-ADR (BPTS) has a market capitalization of 94.20M USD. This makes BPTS a Micro Cap stock.
BIOPHYTIS SA-ADR (BPTS) currently has 26 employees.
BIOPHYTIS SA-ADR (BPTS) has a resistance level at 12.53. Check the full technical report for a detailed analysis of BPTS support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BPTS does not pay a dividend.
BIOPHYTIS SA-ADR (BPTS) will report earnings on 2024-09-25.
BIOPHYTIS SA-ADR (BPTS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.8).
Over the last trailing twelve months BPTS reported a non-GAAP Earnings per Share(EPS) of -7.8. The EPS increased by 63.64% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -134.02% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 38% to BPTS. The Buy consensus is the average rating of analysts ratings from 8 analysts.